{"id":"NCT02335658","sponsor":"Sumitomo Pharma Co., Ltd.","briefTitle":"Long-term Study of DSP-5423P in Patients With Schizophrenia","officialTitle":"Long-term Study of DSP-5423P in Patients With Schizophrenia <Phase 3>","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-12","primaryCompletion":"2017-05","completion":"2017-05","firstPosted":"2015-01-12","resultsPosted":"2020-11-19","lastUpdate":"2022-04-12"},"enrollment":200,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"DSP-5423P","otherNames":[]}],"arms":[{"label":"DSP-5423P","type":"EXPERIMENTAL"}],"summary":"The study evaluates the long term safety of DSP-5423P in patients with schizophrenia.","primaryOutcome":{"measure":"Adverse Events and Adverse Drug Reactions, Etc.","timeFrame":"week 52","effectByArm":[{"arm":"DSP-5423P (Cohort 1)","deltaMin":82,"sd":null},{"arm":"DSP-5423P (Cohort 2)","deltaMin":92,"sd":null},{"arm":"DSP-5423P (Overall)","deltaMin":174,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["31883082"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":97},"commonTop":["Nasopharyngitis","Application site erythema","Application site pruritus","Akathisia","Insomnia"]}}